These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 12602079)

  • 41. Missing data in trial-based cost-effectiveness analysis: the current state of play.
    Noble SM; Hollingworth W; Tilling K
    Health Econ; 2012 Feb; 21(2):187-200. PubMed ID: 22223561
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Probabilistic sensitivity analysis for decision trees with multiple branches: use of the Dirichlet distribution in a Bayesian framework.
    Briggs AH; Ades AE; Price MJ
    Med Decis Making; 2003; 23(4):341-50. PubMed ID: 12926584
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-effectiveness analysis when the WTA is greater than the WTP.
    Willan AR; O'Brien BJ; Leyva RA
    Stat Med; 2001 Nov; 20(21):3251-9. PubMed ID: 11746316
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The performance of a Bayesian value-based sequential clinical trial design in the presence of an equivocal cost-effectiveness signal: evidence from the HERO trial.
    Welch C; Forster M; Ronaldson S; Keding A; Corbacho-Martín B; Tharmanathan P
    BMC Med Res Methodol; 2024 Jul; 24(1):155. PubMed ID: 39030495
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Industry sponsored bias in cost effectiveness analyses.
    John-Baptiste A; Bell C
    BMJ; 2010 Oct; 341():c5350. PubMed ID: 20943724
    [No Abstract]   [Full Text] [Related]  

  • 46. Using Bayesian modeling in frequentist adaptive enrichment designs.
    Simon N; Simon R
    Biostatistics; 2018 Jan; 19(1):27-41. PubMed ID: 28520893
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bayesian estimation of cost-effectiveness from censored data.
    Heitjan DF; Kim CY; Li H
    Stat Med; 2004 Apr; 23(8):1297-309. PubMed ID: 15083484
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Planning the efficient allocation of research funds: an adapted application of a non-parametric Bayesian value of information analysis.
    Karnon J
    Health Policy; 2002 Sep; 61(3):329-47. PubMed ID: 12098524
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Expected value of information and decision making in HTA.
    Eckermann S; Willan AR
    Health Econ; 2007 Feb; 16(2):195-209. PubMed ID: 16981193
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bayesian approaches in medical device clinical trials: a discussion with examples in the regulatory setting.
    Bonangelino P; Irony T; Liang S; Li X; Mukhi V; Ruan S; Xu Y; Yang X; Wang C
    J Biopharm Stat; 2011 Sep; 21(5):938-53. PubMed ID: 21830924
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Classic or Bayesian research design and analysis. Does it make a difference?
    Bloom BS; de Pouvourville N; Libert S
    Int J Technol Assess Health Care; 2002; 18(1):120-6. PubMed ID: 11987435
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Incorporating historical information in biosimilar trials: Challenges and a hybrid Bayesian-frequentist approach.
    Mielke J; Schmidli H; Jones B
    Biom J; 2018 May; 60(3):564-582. PubMed ID: 29532950
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An investment appraisal approach to clinical trial design.
    Backhouse ME
    Health Econ; 1998 Nov; 7(7):605-19. PubMed ID: 9845254
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A framework for cost-effectiveness analysis from clinical trial data.
    O'Hagan A; Stevens JW
    Health Econ; 2001 Jun; 10(4):303-15. PubMed ID: 11400253
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bayesian randomized clinical trials: From fixed to adaptive design.
    Yin G; Lam CK; Shi H
    Contemp Clin Trials; 2017 Aug; 59():77-86. PubMed ID: 28455232
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal.
    Hettle R; Corbett M; Hinde S; Hodgson R; Jones-Diette J; Woolacott N; Palmer S
    Health Technol Assess; 2017 Feb; 21(7):1-204. PubMed ID: 28244858
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Use of implicit and explicit bayesian methods in health technology assessment.
    Cooper NJ; Spiegelhalter D; Bujkiewicz S; Dequen P; Sutton AJ
    Int J Technol Assess Health Care; 2013 Jul; 29(3):336-42. PubMed ID: 23863191
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Theory and practical use of Bayesian methods in interpreting clinical trial data: a narrative review.
    Ferreira D; Barthoulot M; Pottecher J; Torp KD; Diemunsch P; Meyer N
    Br J Anaesth; 2020 Aug; 125(2):201-207. PubMed ID: 32600802
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Methods for incorporating covariate adjustment, subgroup analysis and between-centre differences into cost-effectiveness evaluations.
    Nixon RM; Thompson SG
    Health Econ; 2005 Dec; 14(12):1217-29. PubMed ID: 15945043
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A case for Bayesianism in clinical trials.
    Berry DA
    Stat Med; 1993 Aug; 12(15-16):1377-93; discussion 1395-404. PubMed ID: 8248653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.